The real etiology of Alzheimer’s disease (AD) is still unclear while several risk factors have been recognized to catalytically affect the early onset and the progression of the disease. According to latest studies, AD can be categorized according to risk factors, symptoms, and pathophysiological lesions into 8 different categories. Furthermore, these 8 categories can be analyzed in depth, by adding potential biomarkers in each category which have been proved to affect the severity of the disease.

AD Dementia: The social function, the composite activities of the daily life are obstructed. This state is the threshold between memory changes and in one more cognitive factor.
Alzheimer’s Pathology: Senile Plaques and neurofibrillary tangles, loss of neuronal synapses, amyloid deficits in the vascular cerebral cortex.
Atypical AD: Progressive aphasia, Logopenic aphasia, frontal AD morphology and cortical atrophy at the posterior section. Also is supported from amyloidosis biomarkers in brain or CSF.
MCI: Individuals that abstain from the clinicobiological character of AD and also have measurable MCI. Those individuals may suffer from AD, but there is no evidence for AD.
Mixed AD: Incidents that validate the diagnostic AD requirements for typical AD and there are disorders such as cerebrovascular disease or Lewy Bodies disease.
Preclinical States of AD: This state includes an in vivo amyloidosis evidence of the brain, or individuals whose families have the autosomal dominant mutation of AD.
Prodromal AD: Clinical Symptoms, memory disorders, Hippocampal volume loss and biomarkers of CSF that lead to AD pathology.
Typical AD: Progressive memory loss, cognitive disorders and neuropsychiatric modifications.

While several attempts at reducing AD severity have been already presented mainly targeting the symptomatic treatment, there is still no holistic therapy that can effectively reverse AD. For many scientists and pharmaceuticals companies there are several and different treatment approaches like cholinesterase inhibitors, NMDA receptor antagonist, b-secretase inhibitors, c-secretase inhibitors, a-secretase stimulators, tau inhibitors, immunotherapy, naturaceuticals and nanodrugs even though the more secure solution seems to be the early diagnosis of brain lesions, pathophysiological alterations and obvious the case of early and secure prediction.